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Abstract
The arsenal of cancer therapies has evolved to target T lymphocytes and restore their capacity to destroy tumor cells. T cells 
rely on diacylglycerol (DAG) to carry out their functions. DAG availability and signaling are regulated by the enzymes 
diacylglycerol kinase (DGK) α and ζ, whose excess function drives T cells into hyporesponsive states. Targeting DGKα is a 
promising strategy for coping with cancer; its blockade could reinstate T-cell attack on tumors while limiting tumor growth, 
due to positive DGKα functions in several oncogenic pathways. Here, we made a side-by-side comparison of the effects of 
commercial pharmacological DGK inhibitors on T-cell responses with those promoted by DGKα and DGKζ genetic deletion 
or silencing. We show the specificity for DGKα of DGK inhibitors I and II and the structurally similar compound ritanserin. 
Inhibitor treatment promoted Ras/ERK (extracellular signal-regulated kinase) signaling and AP-1 (Activator protein-1) 
transcription, facilitated DGKα membrane localization, reduced the requirement for costimulation, and cooperated with 
enhanced activation following DGKζ silencing/deletion. DGKiII and ritanserin had similar effects on TCR proximal sign-
aling, but ritanserin counteracted long-term T-cell activation, an effect that was potentiated in DGKα−/− cells. In contrast 
with enhanced activation triggered by pharmacological inhibition, DGKα silencing/genetic deletion led to impaired Lck 
(lymphocyte-specific protein tyrosine kinase) activation and limited costimulation responses. Our results demonstrate that 
pharmacological inhibition of DGKα downstream of the TCR provides a gain-of-function effect that amplifies the DAG-
dependent signaling cascade, an ability that could be exploited therapeutically to reinvigorate T cells to attack tumors.
Keywords Diacylglycerol kinase · Cancer immunotherapy · Lck · T-cell activation · R59949 · Serotonin receptors
Abbreviations
5-HT  Serotonin
5-HTR  Serotonin receptor
AP-1  Activator protein-1
CNB  Centro Nacional de Biotecnología
CSIC  Consejo Superior de Investigaciones Científicas
DAG  Diacylglycerol
DGK  Diacylglycerol kinase
DGKi  DGK inhibitor
ERK  Extracellular signal-regulated kinase
HM-1  Human muscarinic receptor-1
Lck  Lymphocyte-specific protein tyrosine kinase
NFAT  Nuclear factor of activated T cells
PLC  Phospholipase C-gamma
WT  Wild type
Introduction
Harnessing productive T-cell responses to tumors is an effec-
tive strategy in the fight against cancer. Engineering  CD8+ 
T cells to express CAR shows excellent results for treatment 
of hematological malignancies [1]. The success of this strat-
egy for solid tumor therapy has nonetheless proven limited, 
which suggests that even artificial strong TCR signals do 
not impede intrinsic tumor-triggered inhibitory programs 
in TIL [2]. Antibodies that block receptors with negative 
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regulatory functions in TIL (immune checkpoint-blocking 
Ab) have yielded excellent results in treatment of melanoma 
and other solid tumors [3, 4]. The inhibition of cytosolic 
regulators that limit TCR signal strength represents another 
means to overcome tumor-induced immunosuppression [5].
Diacylglycerol kinases (DGK) transform diacylglycerol 
(DAG) into phosphatidic acid (PA), thus limiting DAG-reg-
ulated functions [6]. T lymphocytes express two isoforms, 
DGKα and ζ, which operate downstream of the TCR [7]. 
Excessive DGKα/ζ function attenuates DAG-dependent Ras/
ERK (extracellular signal-regulated kinase)/AP-1 (activator 
protein-1) and PKCθ/NFκB transcription, which produces 
an imbalance of these pathways relative to  Ca2+-mediated 
NFAT (nuclear factor of activated T cells) activation. Nega-
tive regulators of TCR signals, including immune check-
points, ubiquitin ligases, and/or phosphatases, have NFAT-
responsive regulatory elements in their promoters [8]; as a 
result, excessive DGK-dependent DAG consumption drives 
T cells into hyporesponsive, anergic states. The anergy-
resistant phenotype of DGKα/ζ-deficient mice confirms their 
contribution as intrinsic inhibitors of T-cell responses [9].
Experimental evidence suggests that enhanced DGK 
function/expression in TIL limits tumor destruction. When 
injected into nude mice bearing engrafted mesothelioma 
tumors, tumor-infiltrating human CAR T cells show higher 
DGKα/ζ expression than spleen-isolated cells [5]. DGKα 
expression is also enhanced in TIL isolated from human 
renal tumors [10]. These studies support a rationale for tar-
geting DGKα/ζ in the development of anticancer therapies. 
Indeed, the impaired cytotoxic activity of renal TIL and mes-
othelioma-infiltrated CAR T cells can be recovered in vitro 
after treatment with commercial DGK inhibitors (DGKi) [5, 
10]. These drugs are stronger inhibitors of DGKα than of 
DGKζ [11]. The reversal of hypofunctional TIL phenotypes 
by DGKi contrasts with the observation that DGKα−/− CTL 
does not show enhanced cytotoxicity [12]. The design of 
effective therapies to limit DGK activation demands a better 
understanding of isoform-specific functions, as well as of the 
mechanisms triggered by DGK inhibition.
We undertook a detailed study of the results of pharma-
cological blockade of DGKα activity compared to those 
fostered by its genetic deletion/silencing. We compared the 
effects of DGKiI/II with those of ritanserin, a structurally 
similar compound originally conceived to treat mental dis-
orders [13, 14]. Initially characterized as a serotonin (5-HT) 
type 2 receptor (5-HTR2) antagonist [13, 14], ritanserin 
was recently shown to inhibit DGKα in vitro [15]. DGKiI 
(R59022) and II (R59949) have restricted benefit in vivo, 
since they are effective in the micromolar range and have 
limited solubility [11, 16]. Ritanserin has superior phar-
macokinetic properties and is considered safe for human 
use [17], suggesting its potential use for DGKα inhibition. 
Our experiments confirmed DGKi and ritanserin as DGKα 
inhibitors, as their effects were lost after DGKα silencing 
or genetic deletion, but were maintained in DGKζ-silenced/
deleted cells. DGKi and ritanserin enhanced early T-cell 
signaling, but ritanserin antagonism of specific 5-HTR 
reduced expression of activation markers, which limited 
its effectiveness as a DGKα inhibitor. DGKα silencing or 
genetic deletion correlated with impaired Lck (lympho-
cyte-specific protein tyrosine kinase) activation and lim-
ited costimulation responses. In contrast, pharmacologi-
cal DGKα targeting provides a gain-of-function effect that 
amplifies T-cell responses, and must be considered in the 
search for and design of DGK-based therapeutic strategies.
Materials and methods
Mice
C57BL/6J-DGKα−/− and the OT-I DGKα−/− and OT-I 
DGKζ−/− mice have been described [9, 18, 19].
Reagents
Carbachol, R59949, R59022, ritanserin, and ketanserin were 
from Sigma-Aldrich. OVA peptides were from AnaSpec.
Isolation, culture, and stimulation of murine 
and human T cells
Thymus, spleen, or LN was purified from 6- to 12-week-
old mice. Cells were cultured in complete RPMI medium 
(cRPMI), consisting of RPMI (Invitrogen) with 10% heat-
inactivated FBS (Invitrogen), 2  mM L-glutamine, 1% 
HEPES (Sigma). cRPMI was supplemented with penicillin 
and streptomycin (100 U/ml), and 50 µM 2-ME (37 °C, 5% 
 CO2). TCR crosslinking of thymocytes and long-term LN 
stimulation for activation marker expression analysis were 
as described [19].
Splenocytes from OT-I transgenic mice were stimulated 
with  OVA257−264 (SIINFEKL), Q4 (SIIQFEKL), and Q4H7 
(SIIQFEHL) peptides [19].
For CTL differentiation, LN cells from OT-I mice were 
activated with 10 nM  OVA257−264 (48 h), and then diluted 
 (105 cells/ml) and cultured with 100 U/ml IL-2 (4 days).
Human leukemic Jurkat T cells (ATCC) were cultured 
in cRPMI and stimulated with anti-CD3 alone or with anti-
CD28  (107 cells/ml, 1 µg/ml of each mAb) for indicated 
times [19]. The J-HM1-2.2 cell line was generated by stable 
transfection of the human muscarinic receptor-1 (HM-1) in 
Jurkat cells [20] and stimulated with 50 µM carbachol for 
indicated times.
PBMC were obtained from healthy donors, prepared from 
buffy coats in a Ficoll density gradient, and  CD8+ T cells 
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purified using an enrichment kit (Stem Cell Technologies). 
Cells were cultured in cRPMI at a 1:3.5 ratio with tosyl-
activated magnetic beads (Dynabeads M-450; Thermo Sci-
entific) coated according to manufacturer’s protocols with 
100% control IgG1 (R&D Systems), or with 8% anti-CD3 
(HIT3a, BD Biosciences), 10% anti-CD28 (CD28.2, Bio-
Legend), and 82% control IgG1 or 82% PD-L1-Fc chimera 
protein (R&D Systems).
After stimulation, cells were collected and incubated with 
indicated Ab and analyzed by flow cytometry, or were lysed 
and analyzed by western blot according to standard proto-
cols [19]. Unless otherwise indicated in the figure, R59949, 
R59022, ritanserin, or ketanserin was added to a 15 µM 
concentration.
Plasmids and transfection
Silencing experiments and cell transfection by electropora-
tion were as reported using Gene Pulser II (BioRad) [19]. 
The GFP-fused DGKα constructs have been described [21]. 
Reporter plasmids for AP-1 and NFκB were constructed in 
the pGL3 basic vector (Promega) using a tandem of four 
AP-1 canonic binding sites and the NFκB-containing region 
of the human CD69 promoter, respectively. The IL-2 pro-
moter was from Addgene.
Flow cytometry analysis
Mouse T cells were stained with anti-CD8-APC eFluor 
780 (BD Biosciences), -CD69-PE and CD25-PE/Cy7 (BD 
Pharmingen). Cell viability was assessed by Live/Dead Fix-
able Violet Cell Stain (Thermo Fisher).
For pERK analysis of OT-I transgenic cells, total sple-
nocytes  (106) were cultured in peptide-containing medium 
(40 min), fixed in 1% paraformaldehyde (10 min, RT), 
and permeabilized using Phosflow Perm Buffer III (BD 
Biosciences; 30 min, 4 °C). Cells were stained for sur-
face markers (anti-mouse CD8 Pacific Blue and -CD44 
PECy5; 15 min, RT), washed, incubated with anti-pERK 
(ERK1 + ERK2; D13.14.4 XP, Cell Signaling; 1 h, RT), 
washed and stained with secondary goat F(ab′)2 anti-rabbit 
IgG (H + L)-PE Ab (Beckman Coulter; 15 min, RT).
Jurkat cells were stained with anti-human CD69-PC5 
and CD25-PE (Beckman Coulter). For pERK analysis in 
Jurkat cells, 2 × 106 cells were stimulated (15 min), fixed 
(10 min, RT; 2% formaldehyde), permeabilized (ice-cold 
90% methanol; 30 min, 4 °C), washed, and suspended in 
staining medium (PBS, 1% BSA, 0.1%  NaN3). Following 
anti-pERK incubation (30 min, 4 °C), cells were washed, 
stained with secondary Ab (30 min, 4 °C) and analyzed.
Human  CD8+ T cells were stained with anti-human CD8-
FITC, -CD69-PC5, and -CD25-PE.
Cells were analyzed in a Gallios flow cytometer (Beck-
man Coulter). Data were analyzed with FlowJo software 
(FlowJo LLC, Ashland, OR). In all cases, MFI refers to the 
positive population for each marker.
Dual luciferase reporter assays
Experiments were performed as described [19]. Cells were 
stimulated with anti-CD3 or -CD3/CD28 or carbachol 
(20 h). Where indicated, DGKi was included in the stimula-
tion. Cells were harvested and assayed for luciferase activ-
ity using the Dual Luciferase Reporter Assay (Promega). 
Luciferase activity was reported relative to renilla luciferase 
activity (RLU).
Immunofluorescence microscopy and western blot
J-HM1-2.2 cells were transfected with the porcine GFP-
DGKα wild type (wt) construct and analyzed [21]. Anti-
bodies used for western blot were anti-pERK, -pSrc fam-
ily kinases Tyr394, -pLck Tyr505, -pPLCγ, and -pZap70 
Tyr319 (Cell Signaling), -p59Lck (Pharmingen), -Zap70 
(BD Transduction Laboratories), -GAPDH (Santa Cruz), 
-GFP (Invitrogen), -PLCγ (Millipore), -phospho-tyrosine 
(clone 4G10; Millipore), -pNFκB Ser311, -DGKζ (Abcam), 
and -α-tubulin mAb (Sigma). Anti-hDGKα was a gift of 
Dr. W. van Blitterswijk (NCI, Amsterdam, The Netherlands) 
[22]. Mouse DGKα was detected using an in-house rabbit 
antibody [23]. HRP-coupled polyclonal goat anti-mouse/
anti-rabbit Ig was from DakoCytomation.
Statistical analysis
Flow cytometry and luciferase data were analyzed with 
GraphPad Prism 5 software. Data are shown as mean ± SEM. 
Samples were assumed to fit normality. When more than two 
conditions were analyzed, we applied ANOVA and Bonfer-
roni post-test analyses. In all cases, differences were con-
sidered statistically non-significant (ns) for p values > 0.05, 
and significant for *p < 0.05; **p < 0.01 and ***p < 0.001.
Results
DGKα pharmacological blockade, but not silencing, 
yields gain‑of‑function effects on ERK/AP‑1 
activation
Jurkat T cells bind 5-HT, although ritanserin, which pref-
erentially blocks the 5-HTR2, has no 5-HT antagonistic 
effects in these cells [24]. This suggests that Jurkat 5-HTR 
are ritanserin-insensitive. We used this cell line to compare 
the effect of R59949 and ritanserin on ERK phosphorylation 
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downstream of TCR and TCR/CD28 stimulation. Flow 
cytometry and western blot analyses showed that both 
drugs enhanced ERK phosphorylation (Fig. 1a, b; Supple-
mentary Fig. 1a). The structurally related molecule R59022 
also enhanced ERK activation, but the structurally distinct 
5-HTR2 antagonist ketanserin did not (Supplementary 
Fig. 1b). This finding indicated that the effects of ritanserin 
and related compounds on ERK were mediated through 
DGK inhibition rather than by 5-HTR2 antagonism.
Tumor cells can become refractory to T-cell killing by 
losing highly immunogenic Ag; remaining tumor Ag could 
have low affinity for their cognate TCR [25]. DGK inhi-
bition or elimination could potentially increase the T-cell 
response to low affinity Ag, but could also render T cells 
hyper-responsive, leading to autoimmunity. We analyzed the 
effect of pharmacological DGK inhibition and deletion on 
different degrees of antigenic stimulation, using the OT-I 
mouse model, in which  CD8+ T cells can be stimulated with 
the cognate peptide (OVA) or with the Q4 and Q4H7 vari-
ants, which have intermediate and low affinity for the TCR, 
respectively [26].
Flow cytometry analysis of the stimulated splenocytes 
confirmed that the number of pERK-positive cells increased 
with peptide affinity, mainly in the  CD44low subset. DGK 
deficiency increased the percentage of OT-I  pERK+ cells 
and the intensity of ERK phosphorylation per cell (Fig. 1c). 
These increases were significant in DGKζ−/− cells, as in a 
previous report [27], but not for DGKα−/− cells (Fig. 1d; 
Supplementary Fig. 2a). R59949 increased the number of 
 pERK+ cells in the  CD44low population across the affinity 
range (Fig. 1c). After normalization to basal conditions, we 
observed that in wt cells, R59949 significantly increased the 
percentage of  pERK+ cells and MFI at intermediate affinity. 
The inhibitor had a similar effect in DGKζ−/− cells, whereas 
the DGKα−/− cells showed no increase after R59949 treat-
ment (Fig. 1e; Supplementary Fig. 2b). These data suggest 
that R59949-mediated DGKα inhibition reduced the TCR 
threshold for intermediate-affinity Ag.
Treatment of differentiated CTL with ritanserin or 
R59949 also enhanced ERK phosphorylation when 
cells were challenged with OVA-loaded APC. CTL from 
DGKα−/− mice showed enhanced ERK phosphorylation that 
was not increased by R59949 treatment, further confirm-
ing loss of DGKi effect in DGKα−/− cells (Supplementary 
Fig. 2c).
DAG-mediated regulation of the Ras/ERK pathway in 
response to TCR activation activates AP-1-mediated tran-
scription. We evaluated ritanserin and R59949 effects on 
AP-1 transcription using parental and Jurkat T cells silenced 
for each DGK isoform (Fig. 2a). Both inhibitors enhanced 
TCR-dependent AP-1 transcription in parental cells 
(Fig. 2b). DGKα silencing had no effect, whereas DGKζ 
silencing enhanced transcription to nearly the same extent 
as pharmacological blockade in controls (Fig. 2b). Inhibitor 
treatment further enhanced AP-1 transcription after DGKζ 
silencing, with a partial effect after DGKα silencing, prob-
ably due to residual DGKα expression (Fig. 2a).
We evaluated the effect of the two inhibitors in Jurkat T 
cells expressing a constitutive active DGKα mutant. Dele-
tion of the two N-terminal EF-hand domains in DGKα 
(DGKαΔEF) triggers an open conformation with enhanced 
enzyme activity and constitutive plasma membrane localiza-
tion [21]. Cells that transiently express DGKαΔEF showed 
reduced AP-1 activity after TCR stimulation (Fig. 2c, left, 
center). R59949 or ritanserin treatment promoted TCR-
induced luciferase activity in control and DGKαΔEF-
expressing cells, with higher fold induction in cells that 
overexpressed the DGKα mutant (Fig. 2c, right).
Pharmacological DGKα inhibition sustains 
membrane localization
The previous experiments strongly supported ritanserin 
and R59949 specificity for DGKα, and suggested a gain-of-
function effect not mimicked by DGKα depletion. DGKα 
localization to the plasma membrane is limited by its own 
activity, as shown by sustained localization in response to 
receptor stimulation of a kinase-defective DGKα mutant 
and/or to R59949 treatment [21]. We tested whether ritan-
serin-mediated DGKα inhibition correlated with prolonged 
DGKα localization at the cell membrane. For translocation 
experiments, we used J-HM1-2.2 Jurkat cells, a variant that 
constitutively expresses the carbachol receptor; this allows 
analysis of rapid DGKα translocation kinetics using a GFP-
DGKα-expressing plasmid [21]. Carbachol addition to GFP-
DGKα-expressing J-HM1-2.2 cells induced rapid, transient 
translocation of the recombinant protein to the membrane 
(Fig. 2d, top). Ritanserin addition mimicked the effect of 
both inhibitors, promoting sustained GFP-DGKα membrane 
localization (Fig. 2d, bottom) and enhanced AP-1 transcrip-
tion (Fig. 2e).
Fig. 1  DGK control of the ERK axis. a Phosphoflow analysis of ERK 
phosphorylation in Jurkat T cells stimulated with anti-CD3 or -CD3/
CD28 mAb, alone or with the DGKi. The percentage of  pERK+ cells 
is shown. b Cells were stimulated as in a and pERK evaluated by 
western blot. Normalized values for pERK/GAPDH ratios are indi-
cated beneath the blots. Values were normalized to the unstimulated 
time point = 1.0. c–e Splenocytes from wt or  DGK−/− OT-I transgenic 
mice were stimulated with the indicated peptides, with DMSO or 
R59949. ERK1/2 phosphorylation and CD44 expression were deter-
mined by flow cytometry. c Representative biparametric analysis of 
 CD44+ and  pERK+ in  CD8+ cells of each genotype. d Percentage 
of  pERK+ cells in the  CD44low population for the three genotypes. e 
Effect of R59949 on the percentage of  pERK+ cells in each genotype 
was determined after normalization to basal conditions. Results sum-
marize two experiments (n = 3/genotype). c–e Data were analyzed 
using two-way ANOVA and Bonferroni post-test. Significant differ-
ences are indicated
◂






971Cancer Immunology, Immunotherapy (2018) 67:965–980 
1 3
DGKα inhibition amplifies TCR signals
The effect of the inhibitors on DGKα subcellular localiza-
tion and on activation of the ERK/AP-1 axis suggests that 
membrane targeting of the inactive enzyme has positive 
functions that cannot be reproduced by enzyme silencing. 
Membrane localization of DGKα in response to TCR trig-
gering requires of Lck (Lymphocyte-specific protein tyros-
ine kinase) phosphorylation [28]. In metastatic tumor cell 
lines, DGKα association with Src is necessary to sustain 
Src phosphorylation and Src-dependent functions [29]. We 
analyzed the effect of DGKα genetic deletion/silencing on 
TCR-triggered Lck activation.
CD3/CD28 crosslinking of DGKα−/− thymocytes did not 
induce Lck activation as defined by its autophosphoryla-
tion at tyrosine 394 (pTyr394), whereas cells from wt mice 
showed strong phosphorylation (Fig. 3a). Lck autophospho-
rylation in Tyr394 was also markedly reduced in DGKα-
silenced cells, and total phospho-tyrosine profiles showed 
subtle decreases (Fig. 3b; Supplementary Fig. 3b). Follow-
ing DGKα silencing, TCR-triggered Lck dephosphorylation 
at the inhibitory Tyr505 residue was conserved, which sug-
gested normal activation of the CD45 phosphatase. DGKα-
silenced cells showed the characteristic Lck shift that results 
from ERK-dependent Ser/Thr phosphorylation and protects 
the enzyme from SHIP dephosphorylation [30]. This sug-
gested an Lck activation deficit rather than enhanced phos-
phatase activity. TCR triggering of Lck facilitates ZAP70 
activation [31] and subsequent phosphorylation of the LAT 
(linker for activation of T cells) and SLP76 scaffolds, which 
provide anchoring phospho-tyrosine residues for signaling 
proteins such as PLCγ (phospholipase C-gamma). Western 
blot analysis confirmed a reduction in PLCγ and ZAP70 
phosphorylation in DGKα-silenced cells (Fig. 3c). Overex-
posure of blot membranes with the anti-pSrc family kinase 
Ab showed recognition of some proteins whose Mw corre-
sponded to PLCγ and ZAP70, and whose phosphorylation 
was also reduced in DGKα−/− thymocytes (Supplementary 
Fig. 3a).
Contrary to observations in DGKα-depleted cells, phar-
macological DGKα inhibition promoted pTyr394 Lck in 
wt mouse thymocytes and in Jurkat cells (Fig. 3d–e). Total 
phospho-tyrosine profiles showed that the inhibitor pro-
moted subtle increases (Supplementary Fig. 3c–d). These 
results confirm opposite effects of DGKα depletion or inhi-
bition on Lck activation, and suggest that DGKα inhibition 
promotes TCR-dependent Lck activation.
Differential regulation of long‑term effects 
by ritanserin and R59949 in primary mouse T cells
Cell surface expression of the early activation marker CD69 
is a direct measure of Ras/ERK activation, whereas the IL-2 
receptor α chain CD25 is a late activation marker that confers 
high affinity for IL-2 in activated T cells. Analysis of Jurkat 
T cells showed increased percentages of  CD69+CD25+ cells 
in response to R59949 or ritanserin treatment (Supplemen-
tary Fig. 4a–c). Drug treatment increased expression per cell 
of both markers, with greater CD69 increases at early times. 
To determine whether the effects of these drugs were due 
to DGKα targeting and not to 5-HTR, we compared their 
influence on CD69 expression with that of ketanserin. Only 
R59949 and ritanserin enhanced expression of this marker 
(Supplementary Fig. 4d).
R59949 treatment in primary mouse T cells also 
enhanced overall CD69 expression, which was higher after 
CD28 costimulation; contrary to observations in Jurkat T 
cells, ritanserin did not reproduce this effect (Fig. 4a, left). 
The effect of R59949 on CD69 expression was minor in 
DGKα−/− cells, and was lost at later times (Fig. 4a, right). 
R59949 addition to anti-CD3-stimulated wt cells induced 
CD25 levels similar to those found after CD28 costimula-
tion (Fig. 4b, left), an effect again lost in DGKα−/− cells. 
Ritanserin treatment did not increase CD25 expression in wt 
cells and markedly reduced its expression in DGKα−/− cells 
(Fig. 4b, right). R59949 also increased CD69 and CD25 
expression in OT-I mouse  CD8+ T cells (Supplementary 
Fig. 5).
Our experiments suggest a differential effect for ritan-
serin and R59949 in mouse T cells. Mouse T cells synthe-
size 5-HT, which exercises costimulatory functions through 
5-HTR2a [32] and 5-HTR7 [33], whose expression we cor-
roborated by RT-PCR in activated wt and DGKα−/− T cells 
(Supplementary Fig.  6a). As the result of antagonistic 
effects on 5-HT receptors, ritanserin limits murine T-cell 
Fig. 2  Inhibitor specificity for DGKα. a DGKα or DGKζ were 
silenced in Jurkat T cells. Silencing was confirmed by western blot 
using Ab specific for each isoform. b Luciferase activity of an AP-1 
reporter construct was determined after stimulation with anti-CD3 
mAb, alone or with the indicated DGKi. c Expression of a con-
stitutively active version of DGKα (DGKαΔEF) in Jurkat T cells 
was confirmed by western blot with anti-GFP mAb (left). Lucif-
erase activity of the AP-1 reporter was evaluated in parental and 
DGKαΔEF-expressing Jurkat T cells, unstimulated or stimulated 
with CD3 (center). Values were normalized to the basal GFP condi-
tion. Effect of DGKi on luciferase activity of stimulated parental and 
transfected cells (right). Values were normalized to the anti-CD3 con-
dition of each cell type. d J-HM1-2.2  T cells were transfected with 
a plasmid encoding GFP-DGKα; after 24  h, cells were carbachol-
stimulated for indicated times with DMSO or the indicated DGKi, 
and GFP localization was detected by confocal microscopy. e Effect 
of DGKi on luciferase activity of an AP-1 reporter construct in 
J-HM1-2.2 T cells stimulated with carbachol. Data shown as mean ± 
SEM; n = 3 independent transfections per shRNAi/overexpressed con-
struct. Results are representative of at least three independent series 
of experiments with similar results. In b, c data were analyzed using 
two-way ANOVA and Bonferroni post-test; in b, results of compari-
sons are summarized in the table. In e, data were analyzed with one-
way ANOVA and Bonferroni post-test
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Fig. 3  DGKα is a component of the TCR pathway that promotes 
Lck activation. a Thymus T cells from wt or DGKα−/− mice were 
crosslinked with anti-CD3/CD28 for various times, and Lck phospho-
rylation analyzed with indicated Ab. b, c Control or DGKα-silenced 
Jurkat T cells were stimulated with anti-CD3/CD28 for different 
times. Lysates were analyzed with indicated Ab. d Thymus T cells 
from a wt mouse were stimulated with anti-CD3/CD28 alone or with 
R59949 for indicated times. Lck-activating phosphorylation was ana-
lyzed by western blot. e Jurkat cells were stimulated and analyzed 
as in d. In a–e Lck or ZAP70, α-tubulin, and GAPDH were used as 
loading controls. Normalized values are indicated beneath the blots. 
In all cases, results are representative of three experiments with simi-
lar results
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proliferation and CD25 induction triggered by pharma-
cological agents [34]. Ligand competition assays indicate 
that R59949 is less effective than ritanserin in antagonizing 
5-HTR7 [15]. Differential 5-HTR7 targeting by R59949 and 
ritanserin could thus explain their distinct effects on T-cell 
activation; this is supported by observations that ketanserin 
also reduced CD69 and CD25 expression in primary mouse 
cells (Supplementary Fig. 6b-c).
DGKα inhibition cooperates with DGKζ silencing 
for NFκB‑regulated transcription
Our experiments in primary T cells showed that pharma-
cological targeting of DGKα enhances CD25 expression, a 
T-cell activation signature dependent on the costimulatory 
pathway. We recently identified DGKζ predominance over 
DGKα in the regulation CD28-dependent signals that ulti-
mately control NFκB transcription [19]. We tested whether 
in contrast to DGKα silencing, pharmacological DGKα 
inhibition enhances NFκB activation. R59949 treatment of 
CD3/CD28-stimulated Jurkat T cells increased NFκB tran-
scription, with a lesser ritanserin effect (Fig. 5a). NFκB-
regulated transcription did not increase in DGKα-silenced 
Jurkat T cells, confirming the previous findings [19], and 
as predicted, pharmacological inhibitors had a negligible 
effect. In contrast, inhibitor treatment further enhanced 
NFκB transcription in DGKζ-silenced cells (Fig. 5a). In 
accordance with its effect on NFκB transcription activity, 
R59949 increased NFκB phosphorylation and IκB degrada-
tion (Fig. 5b).
The NFκB pathway is crucial for IL-2 expression. The 
IL-2 promoter has two NFκB recognition sites that ensure 
IL-2 expression in fully activated cells, and deficient IL-2 
production is a hallmark of anergic cells [35]. Silencing 
of DGKζ, but not DGKα, enhances IL-2 promoter activa-
tion [19], as confirmed here. As seen for AP-1 and NFκB 
transcription, we observed cooperation between DGKα 
pharmacological inhibition and DGKζ silencing (Fig. 5c). 
These data corroborate experiments in DGKζ−/− mice show-
ing that R59949 enhances the anergy-resistant phenotype 
of DGKζ−/− primary T cells [36], and confirm that DGKα 
inhibition amplifies TCR and costimulatory signals, even in 
the absence of DGKζ.
Effect of DGKα inhibition in PBMC
DGKα limits naïve T-cell activation, but is crucial for main-
taining the hypofunctional state of TIL [10]. Tumor cells 
promote T-cell anergy by upregulating negative regulators 
of T-cell function such as cytosolic molecules and inhibi-
tory receptors. The PD-1/PD-L1 axis is a central target of 
anti-tumor immunotherapies [37]; this interaction enables 
recruitment of tyrosine phosphatase SHP2, which limits 
activation downstream of the TCR [38]. Pharmacologi-
cal DGKα inhibition enhanced Lck activation, which sug-
gests that this function competes with that of PD-1. Using 
a well-characterized model [39], we tested the effect of 
R59949-dependent DGKα inhibition in human healthy 
donor T cells fully stimulated with beads coated with 
anti-CD3/CD28 Ab alone or with PD-L1. As we found 
in mouse T cells and the Jurkat T-cell line, R59949 treat-
ment of human primary T cells increased the percentage 
of  CD69+CD25+ T cells and expression of both markers 
(Fig. 6; Supplementary Fig. 7).
PD-1 triggering greatly reduced T-cell activation, an 
effect that R59949 did not reverse completely (Fig. 6a). 
Comparison of normalized values nonetheless showed that 
R59949 potentiated the percentage of double-positive cells 
and CD25 expression, regardless of PD-1 (Fig. 6b-d). We 
suggest that since PD-1 limits TCR tyrosine signaling, it 
also limited DGKα activation and, therefore, the amount of 
DGKα accessible to the inhibitor.
Discussion
DGK-mediated consumption of DAG generated in response 
to Ag recognition offers an opportunity for therapeutic 
manipulation of the immune response. Several studies indi-
cate that DGKζ predominates over DGKα in TCR response 
control [19, 40, 41]. A minor DGKα contribution is prob-
ably the result of TCR/costimulation-triggered mechanisms 
that lead to early DGKα inhibition [42] and, at later times, 
to transcriptional repression [18]. Although at first glance, 
this would discourage use of DGKα in favor of DGKζ as a 
therapeutic target, additional considerations support interest 
in DGKα. In conditions in which costimulatory pathways 
are lacking or IL-2 concentration is low, DGKα might be 
activated disproportionately [18]. Increased DGKα levels 
are found in pathological states, as is the case of tumor-
infiltrating T and NK cells [10, 43]. DGKα expression also 
increases in cancer cell lines forced to grow in conditions 
that mimic the tumor microenvironment, or are treated with 
anti-tumor drugs [29]. DGKα blockade reduces in vivo 
tumor cell growth in models of xenografted cancer cells 
[29, 44]. The dual function of DGKα can thus be exploited 
to block tumor growth and enhance the anti-tumor immune 
response. Detailed understanding of the effects of DGKα 
pharmacological inhibition is needed to delineate its use as 
a drug target and to define the characteristics desired in new 
inhibitors. Here we compared the effects of DGKiI and II 
and ritanserin to those of enzyme silencing or deletion in 
distinct TCR-activated pathways.
Our study addressed ritanserin function as a DGKα 
inhibitor in T lymphocytes. Ritanserin mimicked R59949 
effects and promoted early T-cell signaling, but these two 
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inhibitors had distinct long-term effects. Differences were 
more pronounced in primary mouse lymphocytes, in which 
ritanserin repressed CD25 expression. This negative effect 
of ritanserin concurs with its 5-HTR2 antagonist effect in 
mouse T cells [34], and was more evident in the absence 
of DGKα. We propose that differential 5-HTR7 targeting 
by R59949 and ritanserin explains their distinct long-term 
effects. Ligand competition assays showed that R59949 and 
R59022 have antagonist activity to all 5-HTR, although 
R59949 blocks 5-HTR2c and 5-HTR7 less effectively than 
R59022 [15], which more closely resembles ritanserin. The 
expression pattern of distinct 5-HTR in PBMC and in TIL 
must thus be considered for potential ritanserin repositioning 
as a T-cell modulator.
Our studies validate DGKα targeting by R59949 and 
demonstrate that DGKα inhibition has no effect on basal 
ERK phosphorylation or CD69 expression. This finding 
confirms that, despite DGKα abundance in naïve T cells, 
its inhibition only amplifies Ras/ERK signaling after TCR 
triggering. This correlates with the DGKα requirement for 
TCR-derived signals for activation, including Lck-dependent 
phosphorylation and  Ca2+ binding. It also supports obser-
vations that, at difference from DGKζ, genetic deletion of 
DGKα has no effect in basal conditions [19]. Our data show-
ing lack of R59949 or ritanserin gain-of-function effects on 
DGKα-silenced or -deficient cells argue for preferential tar-
geting of DGKα. The increased R59949 action in DGKζ-
lacking cells suggests cooperative control of TCR-derived 
signals by both isoforms.
As R59949 binds the DGKα catalytic region [16], we 
hypothesized that this leads to membrane localization of the 
enzyme in a conformation that increases its scaffolding and 
TCR-triggering functions. The inhibitory effect might thus 
be envisaged as gain-of-function, which would correlate 
with reported DGKα inhibition by costimulatory signals 
[42]. This hypothesis is supported by DGKα maintenance 
at the plasma membrane as induced by R59949 and its ana-
logs (R59022 and ritanserin). TCR stimulation results in a 
 Ca2+ increase and tyrosine phosphorylation, signals needed 
to induce the conformational changes necessary for DGKα 
binding to the membrane; at the membrane,  Mg2+ and ATP 
would help stabilize R59949 binding [16]. Ritanserin binds 
to the DGKα catalytic domain and to its first C1 domain 
[45]; the open membrane-bound enzyme might expose its 
C1 domains, which would further potentiate DGKi bind-
ing. These observations imply a link between the kinase 
domain-binding capacity of the inhibitors, DGKα mem-
brane stabilization, and inhibition potency, all of which 
must be considered in the design and evaluation of new 
DGKα inhibitors.
Lck-mediated tyrosine phosphorylation of DGKα is nec-
essary for its association to the T-cell plasma membrane 
[28]. In a previous study, we proposed that DGKα interac-
tion with Src kinases promotes their unclamping and facili-
tates their activation in cancer cells [29]. Our data here sug-
gest a similar DGKα function in promoting Lck activation 
and signaling in T cells. DGKα activity has also been linked 
to endosomal recycling of HLA-I in HeLa cells [46] and 
of integrin in breast cancer cells [47]. Inhibition of DGKα 
in response to costimulatory signals could prevent integrin 
recycling, supporting additional mechanisms for Lck activa-
tion at the plasma membrane. The positive effect of DGKα 
inhibition on Lck described here might also be relevant for 
other Src kinase family members in T cells; for instance, 
DGKα pharmacological inhibition restores PKCθ associa-
tion to Fyn in SAP-deficient T cells [42].
Impaired Lck activation in DGKα-silenced or -deficient 
cells correlated with reduced PLCγ phosphorylation, which 
suggests decreased DAG production and signaling. This 
finding contrasts with the enhanced ERK phosphorylation 
we observed in these cells here and that coincides with pre-
vious reports [9, 19, 48]. Compensation and/or additional 
mechanisms that lead to ERK activation might be opera-
tive, as occurs in the absence of canonical Lck-Zap70-PLCγ 
activation [49]. Whereas ERK activation occurs in such 
conditions, insufficient tyrosine kinase activation might 
affect correct cytoskeleton organization during Ag recogni-
tion. Murine DGKα−/− T cells do not polarize mTOC dur-
ing immune synapse formation, which concurs with actin 
remodeling alterations [12]. This deficit correlates with the 
role of Lck in actin reorganization at the immunological syn-
apse [50]. The potential DAG signaling gain due to DGKα 
loss might be offset by the reduced polarity and DAG pro-
duction [12], which could explain the lesser contribution 
of DGKα compared with that of DGKζ in regulating TCR-
DAG-promoted signals [7].
The PD-1/PD-L1 axis blunts TCR-induced tyrosine 
phosphorylation, and thus the mechanisms that promote 
DGKα aperture/activation, which would limit DGKα tar-
geting by the inhibitors. This would explain why R59949 
treatment is unable to counteract PD-1 effects completely 
in our experiments with human T cells. Experiments 
with renal carcinoma TIL showed PLCγ phosphorylation 
in response to TCR stimulation [10]; this suggests that 
Fig. 4  R59949, but not ritanserin, promotes CD69 and CD25 expres-
sion after TCR triggering and costimulation in mouse T cells. Naïve 
LN cells from C57BL/6J wt and DGKα−/− mice were stimulated 
with anti-CD3 or -CD3/CD28 mAb for indicated times, alone or 
with R59949 or ritanserin. Cell surface CD69 and CD25 expression 
were analyzed by flow cytometry in  CD8+ T cells. MFI are shown 
for a CD69 and b CD25. Data shown as mean ± SEM; n = 3 mice/
genotype; results are representative of three experiments with similar 
results. Data were analyzed using two-way ANOVA and Bonferroni 
post-test
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tyrosine signaling in TIL is not entirely blocked by the 
action of negative receptors, and that DGKα is accessible 
to pharmacological inhibition. Whether alone or combined 
with PD-1-blocking therapies, DGKα inhibition would 
enhance the intensity of antigen-triggered signals and 
foster an immune response to cancer cells.
Fig. 5  DGKα inhibition, but 
not silencing, promotes NFκB 
activity. a Luciferase activity of 
an NFκB reporter construct was 
measured in control and DGKα- 
or DGKζ-silenced Jurkat T 
cells, after stimulation with 
anti-CD3/CD28 mAb alone 
or with R59949 or ritanserin. 
Luciferase activity was cor-
rected using an internal renilla 
luciferase control. b Jurkat T 
cells were stimulated with anti-
CD3/CD28 mAb for indicated 
times, alone or with R59949. 
NFκB phosphorylation and 
IκB degradation were analyzed 
with indicated Ab. α-tubulin 
was used as loading control. 
c IL-2 promoter activity was 
determined as in a. In a, c data 
shown as mean ± SEM; n = 3 
independent transfections per 
shRNAi construct. Results are 
representative of at least three 
independent series of experi-
ments with similar results. Data 
were analyzed using two-way 
ANOVA and Bonferroni post-
test, and results of comparisons 
are summarized in the tables
a
b
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Fig. 6  DGKα inhibition 
increases CD69 and CD25 
expression after TCR costimu-
lation or the PD-1/PD-L1 
immune checkpoint. Purified 
 CD8+ T cells from donors 
(D1-D3), were stimulated with 
IgG, anti-CD3/CD28 or -CD3/
CD28 + PD-L1-coated beads 
for indicated times, alone or 
with R59949. CD69 and CD25 
induction were analyzed by 
flow cytometry. a Percentage of 
 CD69+  CD25+  CD8+ T cells. b 
Fold increase in the percentage 
of activated cells normalized to 
the respective DGKi-untreated 
condition. c Fold change of the 
MFI of CD69 and d CD25 was 
normalized to the respective 
DGKi-untreated condition. Data 
were analyzed using two-way 
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